Stocks making the biggest moves midday: Regeneron, Dominion, Mobileye

Shares of Regeneron, Dominion, Mobileye and Viking were among the most active in midday U.S. trading as takeover reports, clinical data and corporate capital moves pushed volatility higher.

The story developed through separate headlines: reports that NextEra Energy is in talks to acquire Dominion Energy for roughly $66.8 billion sent Dominion shares sharply higher, reflecting expectations of a large utility consolidation. Regeneron’s stock moved amid reports of a drug-pricing agreement with the U.S. administration, which market participants are watching for implications on margins and pricing. Mobileye saw activity tied to secondary offerings and share repurchase programs, while Viking Therapeutics reacted strongly to mid-stage clinical trial data.

Market impact was immediate: Dominion logged double-digit intraday gains on takeover speculation, Viking experienced a steep sell-off after trial details prompted investor concern, and Mobileye’s corporate actions created both buying interest and short-term swings. Regeneron’s moves were more measured but notable given the policy context. These shifts contributed to sector rotations within major indices and increased short-term trading volumes.

In the broader economic and political context, a Dominion-NextEra combination would reshape the U.S. utility landscape as power demand grows from data centers and AI-related infrastructure — a theme increasingly cited by analysts as support for large-scale utility deals. Meanwhile, Regeneron’s engagement on drug pricing reflects continuing regulatory scrutiny of pharmaceutical costs and potential implications for future industry agreements. Biotech price sensitivity to trial outcomes and policy moves remains a key market risk.

Analysts say the near-term outlook is for continued headline-driven volatility: M&A outcomes, regulatory approvals and additional clinical readouts will drive directional moves. For traders, disciplined risk management and attention to news verification will be critical; for longer-term investors, any deal finalization or durable regulatory framework could alter fundamental valuations and sector allocations.